Alignment Healthcare Inc. (NASDAQ:ALHC) saw its shares climb 6.2% on Thursday, erasing part of a sharp decline that followed publication of a whistleblower lawsuit. Market participants pushed the stock higher after analysts characterized Wednesday’s roughly 17% selloff as disproportionate and suggested it may provide a buying opportunity.
The lawsuit was filed by Hakan Kardes, a former Alignment executive, who alleges he was wrongfully terminated and that the company misclassified certain operating expenses as capital expenditures. According to the complaint cited in media reports, those alleged misclassifications could have inflated Adjusted EBITDA by $8-10 million.
Analyst reactions and company review
KeyBanc analyst Matthew Gillmor retained an Overweight rating on the shares and kept a $28.00 price target. Gillmor described the core allegation about the misclassification of technology costs as "dubious," noting that capital expenditure classifications are subject to review by Alignment’s external accountant. Gillmor also pointed out that Alignment’s board engaged outside lawyers and accountants in 2025 to examine the matter and reportedly found no evidence supporting the whistleblower’s claims.
Raymond James analyst John Ransom reiterated a Strong Buy rating. Ransom reported that Alignment told the firm Kardes resigned voluntarily in April 2025 and did not raise accounting concerns while employed. The company says the concern was first raised roughly one month after his resignation, in May 2025. Ransom also noted that the Board’s independent Audit Committee conducted an investigation with outside counsel, and that Deloitte continued to support the company’s accounting treatment as part of its normal audit work.
Timing discrepancy highlighted
Despite those defenses, Ransom observed a timing discrepancy between the company’s account and court filings. The lawsuit alleges Kardes raised the issue internally before stepping down, including conversations with senior executives in March and early April 2025. Ransom described the alleged EBITDA impact as "manageable in the broader context" and not indicative of problems with Alignment’s core earnings engine, while cautioning that the litigation could remain a modest overhang until it is resolved.
Market implications
The episode produced notable near-term volatility for the stock, with large moves tied directly to disclosure of the lawsuit and ensuing analyst commentary. Analysts’ public support and references to external reviews appear to have reassured some investors, contributing to the rebound in the share price.
What remains uncertain
Key unknowns include how the legal claims will progress in court and whether further information will emerge that materially changes the assessment of the alleged misclassification. For now, analysts continue to frame the issue as a legal dispute that does not undermine the company’s primary earnings drivers.